$OPTN
OptiNose, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149465024000154 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $20.44M
YoY Change 3.1%
Cost Of Revenue $2.065M
YoY Change -7.19%
Gross Profit $18.37M
YoY Change 4.4%
Gross Profit Margin 89.9%
Selling, General & Admin $19.48M
YoY Change 8.13%
% of Gross Profit 106.0%
Research & Development $949.0K
YoY Change -25.92%
% of Gross Profit 5.17%
Depreciation & Amortization $65.00K
YoY Change -36.27%
% of Gross Profit 0.35%
Operating Expenses $20.42M
YoY Change 5.87%
Operating Profit -$2.052M
YoY Change 21.13%
Interest Expense $2.519M
YoY Change -49.01%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $467.0K
YoY Change -105.03%
Income Tax
% Of Pretax Income
Net Earnings $467.0K
YoY Change -105.02%
Net Earnings / Revenue 2.29%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 150.8M shares 150.8M shares
Diluted Shares Outstanding 174.4M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.50M
YoY Change 23.5%
Cash & Equivalents $82.50M
Short-Term Investments
Other Short-Term Assets $4.645M
YoY Change 93.54%
Inventory $11.30M
Prepaid Expenses
Receivables $29.77M
Other Receivables $0.00
Total Short-Term Assets $128.2M
YoY Change 30.01%
LONG-TERM ASSETS
Property, Plant & Equipment $670.0K
YoY Change -24.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.135M
YoY Change 12.07%
Total Long-Term Assets $2.805M
YoY Change 0.65%
TOTAL ASSETS
Total Short-Term Assets $128.2M
Total Long-Term Assets $2.805M
Total Assets $131.0M
YoY Change 29.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.777M
YoY Change -24.55%
Accrued Expenses $31.66M
YoY Change 12.96%
Deferred Revenue
YoY Change
Short-Term Debt $126.0M
YoY Change -2.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $162.4M
YoY Change -0.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.187M
YoY Change 60.19%
Total Long-Term Liabilities $1.187M
YoY Change 60.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $162.4M
Total Long-Term Liabilities $1.187M
Total Liabilities $172.1M
YoY Change -3.86%
SHAREHOLDERS EQUITY
Retained Earnings -$741.6M
YoY Change 4.38%
Common Stock $700.5M
YoY Change 10.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$41.10M
YoY Change
Total Liabilities & Shareholders Equity $131.0M
YoY Change 29.2%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $467.0K
YoY Change -105.02%
Depreciation, Depletion And Amortization $65.00K
YoY Change -36.27%
Cash From Operating Activities -$8.833M
YoY Change 99.84%
INVESTING ACTIVITIES
Capital Expenditures $21.00K
YoY Change -88.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.00K
YoY Change -88.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.000K
YoY Change -105.0%
NET CHANGE
Cash From Operating Activities -8.833M
Cash From Investing Activities -21.00K
Cash From Financing Activities -7.000K
Net Change In Cash -8.861M
YoY Change 98.68%
FREE CASH FLOW
Cash From Operating Activities -$8.833M
Capital Expenditures $21.00K
Free Cash Flow -$8.854M
YoY Change 92.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
OPTINOSE, INC.
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
150829507 shares
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29772000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19926000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
11301000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
8052000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4645000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3671000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
128215000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
105333000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
670000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
815000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2135000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1581000 usd
CY2024Q3 us-gaap Assets
Assets
131020000 usd
CY2023Q4 us-gaap Assets
Assets
107729000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3777000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3886000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
32668000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
42411000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
162430000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
176524000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1187000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
611000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
172117000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
777 Township Line Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Yardley
CY2023Q4 us-gaap Liabilities
Liabilities
194335000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
467000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-41097000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3083000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4017000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19475000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001494650
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19067
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
364-3500
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
125985000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
130227000 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112399495 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112399495 shares
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5277000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6502000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64121000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60839000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16674000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-20236000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8700000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7190000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2018000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1974000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
15212000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14436000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25516000 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25516000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149634133 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111996456 shares
us-gaap Net Income Loss
NetIncomeLoss
-21181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25516000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21181000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25516000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1771610
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OPTN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82497000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73684000 usd
CY2024Q3 optn Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
8500000 usd
CY2023Q4 optn Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
17200000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
282000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5481000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4219000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8700000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7190000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1531000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1242000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9847000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12559000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150829507 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150829507 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
151000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
112000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
700393000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
633742000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-741557000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-720376000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-84000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-84000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-41097000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-86606000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131020000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107729000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20437000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19823000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55807000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51122000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2065000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2225000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
949000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1281000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18011000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
22489000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
21517000 usd
us-gaap Costs And Expenses
CostsAndExpenses
72481000 usd
us-gaap Costs And Expenses
CostsAndExpenses
71359000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2052000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1694000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6900000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3200000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
913000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
545000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5294000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4940000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
467000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9294000 usd
CY2024Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
74000 usd
CY2023Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21181000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25516000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
128000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2432000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3249000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1348000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-109000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-346000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174328570 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112230155 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144900726 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111996456 shares
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21181000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25516000 usd
CY2024Q3 optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
CY2023Q3 optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
8700000 usd
optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29881000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174369875 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112230155 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
467000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9294000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
467000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9294000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-86606000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1456000 usd
CY2024Q1 optn Stock Issued During Period Value Vested Restricted Stock Units
StockIssuedDuringPeriodValueVestedRestrictedStockUnits
1000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-14067000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-99215000 usd
CY2024Q2 optn Stock Issued During Period Issuance Of Stock Per Amended Debt Agreement In Value
StockIssuedDuringPeriodIssuanceOfStockPerAmendedDebtAgreementInValue
5750000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55294000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2735000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
165000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7581000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-42853000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1288000 usd
CY2024Q3 optn Stock Issued During Period Value Vested Restricted Stock Units
StockIssuedDuringPeriodValueVestedRestrictedStockUnits
1000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-56624000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1520000 usd
CY2023Q1 optn Stock Issued During Period Value Vested Restricted Stock Units
StockIssuedDuringPeriodValueVestedRestrictedStockUnits
1000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
164000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18847000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-73785000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1499000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2626000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-69660000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
135000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9294000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-77615000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25516000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-10568000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-16471000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46552000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27441000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-255000 usd
optn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
55476000 usd
optn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
166000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
299000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
206000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55436000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
296000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8812000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27400000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73684000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94244000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82496000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66844000 usd
us-gaap Interest Paid Net
InterestPaidNet
18340000 usd
us-gaap Interest Paid Net
InterestPaidNet
13194000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1402000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
890000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OptiNose, Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania and Ewing, New Jersey. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization. Optinose AS was liquidated in October 2023. During 2022, the Company's board of directors also approved the liquidation of Optinose UK, in order to simplify the corporate structure. Optinose UK was liquidated in July 2024.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the Company's proprietary Exhalation Delivery System™ (EDS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82497000 usd
CY2024Q3 optn Working Capital
WorkingCapital
-34215000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-741557000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
31800000 shares
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2024Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
55300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and supplier concentration</span></div>The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers.
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
467000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9294000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25516000 usd
CY2024Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
74000 usd
CY2023Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21181000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25516000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174328570 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112230155 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144900726 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111996456 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21181000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25516000 usd
CY2024Q3 optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
CY2023Q3 optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
8700000 usd
optn Dilutive Securities Effect On Basic Earnings Per Share Fair Value Warrants Adjustments
DilutiveSecuritiesEffectOnBasicEarningsPerShareFairValueWarrantsAdjustments
0 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
393000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9294000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29881000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25516000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174369875 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112230155 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149634133 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111996456 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174328570 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112230155 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144900726 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111996456 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
41305 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
4733407 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174369875 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112230155 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149634133 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111996456 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40777649 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45124399 shares
CY2024Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
8500000 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
8500000 usd
CY2023Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
17200000 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
17200000 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17200000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-8700000 usd
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8500000 usd
CY2024Q3 optn Class Of Warrant Or Right Restriction Common Shares Maximum Ownership If Exercised Percent
ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipIfExercisedPercent
0.0499
CY2024Q3 optn Class Of Warrant Or Right Restriction Common Shares Maximum Ownership Prior To Execution Percent
ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipPriorToExecutionPercent
0.0999
CY2024Q3 optn Class Of Warrant Or Right Restriction Common Shares Maximum Ownership After Effective Waiting Period Percent
ClassOfWarrantOrRightRestrictionCommonSharesMaximumOwnershipAfterEffectiveWaitingPeriodPercent
0.1999
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2272000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2400000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6211000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3281000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2818000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2371000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
11301000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
8052000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5751000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5679000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5081000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4864000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
670000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
815000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
65000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
102000 usd
us-gaap Depreciation
Depreciation
217000 usd
us-gaap Depreciation
Depreciation
281000 usd
CY2024Q3 optn Accrued Product Allowances Current
AccruedProductAllowancesCurrent
19911000 usd
CY2023Q4 optn Accrued Product Allowances Current
AccruedProductAllowancesCurrent
20145000 usd
CY2024Q3 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
4976000 usd
CY2023Q4 optn Accrued Selling Generaland Administrative Current
AccruedSellingGeneralandAdministrativeCurrent
6229000 usd
CY2024Q3 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
262000 usd
CY2023Q4 optn Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
644000 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5481000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6801000 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4666000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1034000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3015000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31664000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41500000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1004000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
911000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1004000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
911000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
32668000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
42411000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5294000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4940000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
15212000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14436000 usd
us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
872000 usd
us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
677000 usd
CY2024Q3 us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
223000 usd
CY2023Q3 us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
201000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
31800000 shares
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
30268000 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1290000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1205000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5481000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4230000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1703101 shares

Files In Submission

Name View Source Status
0001494650-24-000154-index-headers.html Edgar Link pending
0001494650-24-000154-index.html Edgar Link pending
0001494650-24-000154.txt Edgar Link pending
0001494650-24-000154-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
optinose09-30x202410xqrm30.htm Edgar Link pending
optinose09-30x202410xqtk30.htm Edgar Link pending
optinose9-30x202410xqrm906.htm Edgar Link pending
optinose9-30x202410xqtk906.htm Edgar Link pending
optn-20240930.htm Edgar Link pending
optn-20240930.xsd Edgar Link pending
optn-20240930_g1.jpg Edgar Link pending
optn-20240930_g2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
optn-20240930_cal.xml Edgar Link unprocessable
optn-20240930_def.xml Edgar Link unprocessable
optn-20240930_lab.xml Edgar Link unprocessable
optn-20240930_pre.xml Edgar Link unprocessable
optn-20240930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending